Experimental drug tested for rare lung condition after transplant
NCT ID NCT04239989
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested the safety of a drug called itacitinib in 8 adults who developed bronchiolitis obliterans syndrome (a type of lung scarring) after receiving a stem cell transplant from a donor. The goal was to see if the drug could help control the lung disease by blocking certain enzymes. The study was terminated early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRONCHIOLITIS OBLITERANS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can airway cell clues predict a rare lung disease in children?
- New study aims to detect lung damage earlier in young transplant patients
- Can lung MRI replace CT scans for detecting a serious Post-Transplant lung condition?
- Inhaled drug aims to save transplanted lungs from silent threat
- New hope for lung scarring after transplant: belumosudil trial launches
- Inhaled cyclosporine aims to halt lung transplant rejection